Gabriel Schwartz, MSN, NP, explains how mechanisms of action determine the safety of systemic treatments in metastatic colorectal cancer post chemotherapy.
The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are self-held unless noted. I = Immediate Family ...
The patient outcomes with EGFR-mutated advanced non-small-cell lung cancer receiving aumolertinib as first-line treatment. This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting I. This ...
Adding Imfinzi and Avastin to transarterial chemoembolization led to a 23% reduction in the risk of progression or death in patients with liver cancer. Patients with unresectable hepatocellular ...
WASHINGTON - The government delivered a blow to some desperate patients Friday as it ruled the blockbuster drug Avastin should no longer be used to treat advanced breast cancer. Avastin is hailed for ...
Final Phase 2 data show casdozokitug with atezolizumab/bevacizumab achieves a 17.2% complete response rate in HCC patients. Coherus BioSciences, Inc. announced ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback